Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales

Eli Lilly's (LLY) acquisition of Centessa Pharmaceuticals (CNTA) has cleared a major regulatory hurdle with High Court approval in England and Wales. The $7.8 billion transaction—structured at $38.00 per share cash plus contingent value rights up to $9.00—represents a strategic expansion into neurological treatments, specifically excessive daytime sleepiness therapies. This milestone de-risks the deal completion timeline and signals confidence in Centessa's clinical pipeline.

The CVR structure reflects typical pharma M&A risk allocation: Lilly pays base consideration immediately while tying $2.1 billion (27% of deal value) to achievement of three clinical/commercial milestones. This aligns seller and buyer interests on product development execution, suggesting Lilly's confidence in Centessa's assets but appropriate caution on regulatory/commercialization outcomes. The milestone-based component de-risks Lilly's balance sheet while rewarding Centessa shareholders on tangible value creation.

For LLY, this acquisition bolsters its neurology portfolio and diversifies revenue exposure beyond GLP-1 obesity treatments. The deal diversification matters given current market concentration risk in Lilly's blockbuster pipeline. Centessa's clinical-stage profile means near-term revenue accretion is unlikely, but long-term franchise optionality increases—particularly if sleep disorders represent an underserved market segment with pricing power potential.

Sector implication: The approval accelerates consolidation within specialty pharma and validates large-cap biotech M&A activity. This signals continued investor appetite for assets addressing neurological indications and suggests Lilly's capacity to absorb acquisition risk. Competitors may face acquisition pressure, and smaller biotech firms with clinical-stage neurology programs may see valuation support from comparable transaction multiples.